Free Trial
NASDAQ:NEO

NeoGenomics Q2 2025 Earnings Report

NeoGenomics logo
$6.34 -0.38 (-5.58%)
As of 01:10 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NeoGenomics EPS Results

Actual EPS
N/A
Consensus EPS
$0.03
Beat/Miss
N/A
One Year Ago EPS
N/A

NeoGenomics Revenue Results

Actual Revenue
N/A
Expected Revenue
$182.91 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

NeoGenomics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, July 29, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

NeoGenomics Earnings Headlines

Analysts Set NeoGenomics, Inc. (NASDAQ:NEO) PT at $13.83
Bitcoin just humbled Jeff Bezos
Bitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video.
NeoGenomics, Inc. (NEO) - Yahoo Finance
See More NeoGenomics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NeoGenomics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeoGenomics and other key companies, straight to your email.

About NeoGenomics

NeoGenomics (NASDAQ:NEO) (NASDAQ: NEO) is a leading provider of cancer-focused genetic and molecular diagnostic testing services. Founded in 2002 and headquartered in Fort Myers, Florida, the company has built a reputation for delivering high-complexity laboratory testing that supports personalized oncology care. NeoGenomics offers an extensive menu of assays designed to aid in diagnosis, prognosis and therapy selection for a broad range of hematologic and solid tumor cancers.

The company’s core services include next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), cytogenetics, immunohistochemistry (IHC) and flow cytometry, complemented by digital and computational pathology. In addition to clinical testing, NeoGenomics operates a central laboratory services division that provides biomarker testing and companion diagnostics for pharmaceutical and biotechnology companies conducting oncology clinical trials. The integration of laboratory information systems and advanced analytics enables streamlined sample processing and rapid reporting of results.

NeoGenomics has grown through both organic expansion and strategic acquisitions, including the purchase of a leading immunohistochemistry laboratory in 2014 and several specialty genetic testing firms in subsequent years. Its network spans multiple U.S. laboratories in Florida, California, Texas, Tennessee, Washington, New York and New Jersey, alongside European facilities in Basel, Switzerland; Glasgow, U.K.; and Hamburg, Germany. This global footprint allows the company to serve healthcare providers, research institutions and clinical trial sponsors around the world.

Under the leadership of President and Chief Executive Officer Mark J. Erceg and a seasoned management team, NeoGenomics remains focused on advancing cancer diagnostics through technology innovation and rigorous quality standards. The company continues to invest in expanding its test menu, enhancing automation and incorporating new molecular techniques to support precision medicine initiatives and improve outcomes for patients with cancer.

View NeoGenomics Profile

More Earnings Resources from MarketBeat